Review



tim3  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems tim3
    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
    Tim3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tim3/product/R&D Systems
    Average 94 stars, based on 6 article reviews
    tim3 - by Bioz Stars, 2026-06
    94/100 stars

    Images

    1) Product Images from "Single-Cell Profiling Reveals Developmental Trajectories and identifies SYK and TIM3 as Targets in some T Cell Lymphomas"

    Article Title: Single-Cell Profiling Reveals Developmental Trajectories and identifies SYK and TIM3 as Targets in some T Cell Lymphomas

    Journal: bioRxiv

    doi: 10.64898/2026.03.27.714741

    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, TIM3+ T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
    Figure Legend Snippet: (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, TIM3+ T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.

    Techniques Used: Staining, Expressing



    Similar Products

    tim3 galectin 9 pathway  (Galectin Therapeutics)
    86
    Galectin Therapeutics tim3 galectin 9 pathway
    Tim3 Galectin 9 Pathway, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tim3 galectin 9 pathway/product/Galectin Therapeutics
    Average 86 stars, based on 1 article reviews
    tim3 galectin 9 pathway - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    pe anti tim3  (Cytek Biosciences)
    92
    Cytek Biosciences pe anti tim3
    Pe Anti Tim3, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe anti tim3/product/Cytek Biosciences
    Average 92 stars, based on 1 article reviews
    pe anti tim3 - by Bioz Stars, 2026-06
    92/100 stars
    		  Buy from Supplier
    tim3  (R&D Systems)
    94
    R&D Systems tim3
    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
    Tim3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tim3/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    tim3 - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    galectin 9 tim3  (Galectin Therapeutics)
    86
    Galectin Therapeutics galectin 9 tim3
    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
    Galectin 9 Tim3, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/galectin 9 tim3/product/Galectin Therapeutics
    Average 86 stars, based on 1 article reviews
    galectin 9 tim3 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    tim3 galectin 9 expression  (Galectin Therapeutics)
    86
    Galectin Therapeutics tim3 galectin 9 expression
    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
    Tim3 Galectin 9 Expression, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tim3 galectin 9 expression/product/Galectin Therapeutics
    Average 86 stars, based on 1 article reviews
    tim3 galectin 9 expression - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    protein 3 tim3  (Galectin Therapeutics)
    86
    Galectin Therapeutics protein 3 tim3
    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
    Protein 3 Tim3, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/protein 3 tim3/product/Galectin Therapeutics
    Average 86 stars, based on 1 article reviews
    protein 3 tim3 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, TIM3+ T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.

    Journal: bioRxiv

    Article Title: Single-Cell Profiling Reveals Developmental Trajectories and identifies SYK and TIM3 as Targets in some T Cell Lymphomas

    doi: 10.64898/2026.03.27.714741

    Figure Lengend Snippet: (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, TIM3+ T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.

    Article Snippet: Following heat-mediated antigen retrieval, consecutive sections were stained for TIM3 (MAB23652, R&D Systems) and CD30 (M0751, Agilent Dako) both at a 1:50 dilution.

    Techniques: Staining, Expressing